MBX Biosciences, Inc. (MBX) Receives a Buy from Mizuho Securities
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences (MBX) with a $57 price target. The broader market consensus for MBX is Strong Buy, with an average price target of $75.43.
Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $57.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Sarepta Therapeutics, and Relmada Therapeutics. According to TipRanks, Ear has an average return of 2.4% and a 41.44% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $75.43 average price target.